Recce Pharmaceuticals Ltd (ASX:RCE) Annual Report 2025



The latest annual report of Recce Pharmaceuticals Ltd (RCE) was published on 30 Jun 2025. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - RCE Annual Results

Amounts in AUD

Total Revenue
$7.70M
Gross Profit
$-2.94M
EBIT
$-177.96M
Net Tangible Assets
$-3.18M
Net Income
$-21.43M
Capital Expenditures
-

RCE Income Statement 2025 Annual Report

As per the latest Income Statement of RCE, the Net revenue increased by $2.47M (47%) compared to the previous period. The operating income in 2025 increased by - (-). The net income as per the annual report was $-21.43M which decreased by $-3.77M (-21%) compared to previous year.

Income Statement Report (2025/2024)

2025 2024
Total Revenue $7.70M $5.24M
Gross Profit $-2.94M $-2.94M
Operating Income - -
Income Before Tax - -
Net Income $-21.43M $-17.66M

Balance Sheet - RCE 2025 Annual Report

Read further: RCE Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Recce Pharmaceuticals Ltd showed the company increased the cash on balance sheet by $0.00 (0%). The Net tangible assets of RCE on the balance sheet were at $-3.18M which is $0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2025/2024)

2025 2024
Cash $10.69M $10.69M
Total Assets - -
Long Term Debt - -
Total Liabilities $10.77M $10.77M
Total Shareholder Equity - -
Net Tangible Assets $-3.18M $-3.18M

Cash Flow Statement - RCE 2025 Annual Report

The 2025 annual cash flow statement of Recce Pharmaceuticals Ltd showed that the net income decreased by $-3.77M (-21%) compared to previous reporting period. Also the capital expenditure of RCE increased by - (-).

As of 2025, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2025/2024)

2025 2024
Net Income $-21.43M $-17.66M
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

Recce Pharmaceuticals Ltd Annual Report History

Income Statement

Income Statement history of Recce Pharmaceuticals Ltd (ASX:RCE)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2022
Total Revenue $7.70M $5.24M $4.31M $0.00
Cost Of Revenue $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses $0.00 $0.00 $0.00 $0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit $0.00 $0.00 $0.00 $0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense $0.00 $0.00 $0.00 $0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income $-21.43M $-17.66M $-13.08M $-10.99M
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of Recce Pharmaceuticals Ltd (ASX:RCE)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2022
Cash $10.69M $10.69M - -
Total Assets - - - -
Total Liab $10.77M $10.77M - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets $-3.18M $-3.18M - -

Cash Flow Statement

Cash Flow Statement history of Recce Pharmaceuticals Ltd (ASX:RCE)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2022
Net Income $-21.43M $-17.66M - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -